Evidence map›Paper›PMID 42039561›Full record

ArticlebioRxiv : the preprint server for biology2026

Single injection of modified self-amplifying RNA encoding a CD19 bispecific T cell engager mediates long-term malignant B cell clearance.

Kexin Li, Joshua E McGee, Wilson W Wong, Mark W Grinstaff

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Kexin LiDepartment of Biomedical Engineering, Boston University, Boston, MA, USA.ORCID 0009-0000-8965-1560
Joshua E McGeeDepartment of Biomedical Engineering, Boston University, Boston, MA, USA.ORCID 0000-0003-3327-6209
Wilson W WongDepartment of Biomedical Engineering, Boston University, Boston, MA, USA.ORCID 0000-0001-8394-889X
Mark W GrinstaffDepartment of Biomedical Engineering, Boston University, Boston, MA, USA.ORCID 0000-0002-5453-3668

Funding

Synthetic toolkit for precision gene expression control and signal processing in mammalian cellsR01EB029483 · NIBIB · HARVARD UNIVERSITY · PI Ahmad Samir Khalil · 2020 to 2026
$5.0M
Translational Research in BiomaterialsT32EB006359 · NIBIB · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI MARK W. GRINSTAFF, Michelle H Teplensky · 2009 to 2026
$4.2M
Precise tumor targeting with logic CAR circuitsU01CA265713 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI COLSON, YOLONDA L, GRINSTAFF, MARK W. · 2021 to 2025
$2.5M
A self-amplifying RNA-based synthetic nanobody platform for next-generation therapeuticsR01EB038005 · NIBIB · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI Florian Douam, MARK W. GRINSTAFF · 2025 to 2026
$1.3M
Modified saRNA Encoded BiTEs for Lung CancerR01CA296810 · NCI · BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI Yolonda L Colson, MARK W. GRINSTAFF · 2025 to 2026
$1.3M
NCI NIH HHS R01 CA296810NCI NIH HHS U01 CA265713NIBIB NIH HHS R01 EB029483NIBIB NIH HHS R01 EB038005NIBIB NIH HHS T32 EB006359
6 · The paper itself

Abstract

Bispecific T cell engagers (BiTEs) are a novel cancer immunotherapy modality that achieves significant clinical success. However, conventional single-chain variable fragment (scFv)-based BiTE therapy requires continuous intravenous infusion due to BiTE's short half-life, limiting patient access and increasing healthcare cost. Self-amplifying RNA (saRNA), an emerging RNA technology, enables durable protein production

Identifiers

PMID42039561
PMCPMC13105060

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.